Compile Data Set for Download or QSAR
maximum 50k data
Found 1629 with Last Name = 'rauniyar' and Initial = 'v'
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410256((rac)-N-(3-(1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,...)
Affinity DataIC50:  0.00100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410277((rac)-N-(3-(6-hydroxy-6-methyl-1,2,4,4a,5,6-hexahy...)
Affinity DataIC50:  0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410342(N-(3-((4aR,6R)-6-Hydroxy-1,2,4,4a,5,6-hexahydro-[1...)
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410384(US10377770, Example 144)
Affinity DataIC50:  0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410350(US10377770, Example 110)
Affinity DataIC50:  0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410352(US10377770, Example 112)
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410356(US10377770, Example 116 | rac-trans-2-(1,1-Difluor...)
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410387(US10377770, Example 147)
Affinity DataIC50:  0.00300nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410381(US10377770, Example 141)
Affinity DataIC50:  0.00400nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204382(US9242996, 461)
Affinity DataIC50:  0.00431nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410393(US10377770, Example 153)
Affinity DataIC50:  0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410358(2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymet...)
Affinity DataIC50:  0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410231((trans)-2-(1,1-difluoroethyl)-N-(3-(6-hydroxy-1,2,...)
Affinity DataIC50:  0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410362(US10377770, Example 122 | rac-trans-N-(3-(5-(Hydro...)
Affinity DataIC50:  0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410357(2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymet...)
Affinity DataIC50:  0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410363(US10377770, Example 123 | rac-trans-N-(3-(5-(Hydro...)
Affinity DataIC50:  0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410351(US10377770, Example 111)
Affinity DataIC50:  0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204241(US9242996, 315)
Affinity DataIC50:  0.00500nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204384(US9242996, 463)
Affinity DataIC50:  0.00550nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410207((trans)-N-(3-(6-hydroxy-1,2,4,4a,5,6-hexahydro-[1,...)
Affinity DataIC50:  0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410293(N-(3-(5,5-bis(hydroxymethyl)-1,2,4,4a,5,6-hexahydr...)
Affinity DataIC50:  0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410349(US10377770, Example 109)
Affinity DataIC50:  0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410306(2-(1,1-difluoroethyl)-N-(3-(5-(hydroxymethyl)-1,2,...)
Affinity DataIC50:  0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204469(US9242996, 179)
Affinity DataIC50:  0.00612nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204281(US9242996, 360)
Affinity DataIC50:  0.00665nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204470(US9242996, 180)
Affinity DataIC50:  0.00671nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410223(US10377770, Example 12)
Affinity DataIC50:  0.00700nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410399(US10377770, Example 159)
Affinity DataIC50:  0.00700nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410353(US10377770, Example 113)
Affinity DataIC50:  0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410268((trans)-N-(3-(6-methoxy-1,2,4,4a,5,6-hexahydro-[1,...)
Affinity DataIC50:  0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410281(US10377770, Example 43 | US10377770, Example 44)
Affinity DataIC50:  0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410274((rac)-(cis)-N-(3-(6-hydroxy-1,2,4,4a,5,6-hexahydro...)
Affinity DataIC50:  0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204316(US9242996, 395)
Affinity DataIC50:  0.00827nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204294(US9242996, 373)
Affinity DataIC50:  0.00837nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204168(US9242996, 242)
Affinity DataIC50:  0.00875nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204405(US9242996, 478a)
Affinity DataIC50:  0.00900nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410364(US10377770, Example 124)
Affinity DataIC50:  0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410361(N-(5-((4aR,5R)-5-(Hydroxymethyl)-1,2,4,4a,5,6-hexa...)
Affinity DataIC50:  0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410380(US10377770, Example 140)
Affinity DataIC50:  0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410269(US10377770, Example 34)
Affinity DataIC50:  0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410383(US10377770, Example 143)
Affinity DataIC50:  0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410300((rac)-N-(3-(5-(hydroxymethyl)-1,2,4,4a,5,6-hexahyd...)
Affinity DataIC50:  0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204301(US9242996, 380)
Affinity DataIC50:  0.00970nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204270(US9242996, 344)
Affinity DataIC50:  0.00977nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204255(US9242996, 329)
Affinity DataIC50:  0.0100nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410299(2-(1,1-difluoroethyl)-N-(4-methyl-3-(2,4,4a,6-tetr...)
Affinity DataIC50:  0.0100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410218(US10377770, Example 11 | US10377770, Example 9)
Affinity DataIC50:  0.0100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410398(US10377770, Example 158)
Affinity DataIC50:  0.0100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410279(US10377770, Example 41 | US10377770, Example 42)
Affinity DataIC50:  0.0100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM204308(US9242996, 387)
Affinity DataIC50:  0.0100nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1629 total ) | Next | Last >>
Jump to: